- Home
- PROP vs SKYE Comparison
PROP vs SKYE Comparison
Compare PROP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROP
- SKYE
- Stock Information
- Founded
- PROP 2001
- SKYE 2012
- Country
- PROP United States
- SKYE United States
- Employees
- PROP N/A
- SKYE N/A
- Industry
- PROP Investment Bankers/Brokers/Service
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PROP Finance
- SKYE Health Care
- Exchange
- PROP Nasdaq
- SKYE Nasdaq
- Market Cap
- PROP 120.5M
- SKYE 101.3M
- IPO Year
- PROP N/A
- SKYE N/A
- Fundamental
- Price
- PROP $2.47
- SKYE $3.29
- Analyst Decision
- PROP Strong Buy
- SKYE Buy
- Analyst Count
- PROP 5
- SKYE 7
- Target Price
- PROP $8.50
- SKYE $15.50
- AVG Volume (30 Days)
- PROP 2.7M
- SKYE 304.9K
- Earning Date
- PROP 08-12-2025
- SKYE 08-07-2025
- Dividend Yield
- PROP N/A
- SKYE N/A
- EPS Growth
- PROP N/A
- SKYE N/A
- EPS
- PROP N/A
- SKYE N/A
- Revenue
- PROP $88,854,000.00
- SKYE N/A
- Revenue This Year
- PROP $5,710.68
- SKYE N/A
- Revenue Next Year
- PROP $28.49
- SKYE N/A
- P/E Ratio
- PROP N/A
- SKYE N/A
- Revenue Growth
- PROP N/A
- SKYE N/A
- 52 Week Low
- PROP $2.01
- SKYE $1.14
- 52 Week High
- PROP $12.30
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- PROP 38.82
- SKYE 44.67
- Support Level
- PROP $2.01
- SKYE $3.23
- Resistance Level
- PROP $2.83
- SKYE $3.75
- Average True Range (ATR)
- PROP 0.29
- SKYE 0.30
- MACD
- PROP -0.08
- SKYE -0.02
- Stochastic Oscillator
- PROP 26.44
- SKYE 29.76
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.